Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 12/20 | 0.45 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076212 | 0.87 | KDM4E (0.48) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL5348100 | 0.86 | POLB (0.47) | ALDH1A1NOTUMPIK3CDHCRTR2 | |
| SCHEMBL5347384 | 0.83 | NEK2 (0.51) | KDM4EHSD17B10NOTUMHCRTR2 | |
| SCHEMBL27794105 | 0.83 | POLB (0.53) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL12184895 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL30919906 | 0.81 | CCNE2 (0.41) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL30919792 | 0.81 | CCNE2 (0.41) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL30919856 | 0.81 | CCNE2 (0.41) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 | |
| SCHEMBL30919618 | 0.79 | KDM4E (0.46) | KDM4E | |
| SCHEMBL20267965 | 0.78 | KDM4E (0.55) | ALDH1A1KMT2AKDM4EMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600874-B1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | DCK, DTYMK, TYMS | ALDH1A1 725/4885KMT2A 1393/4885KDM4E 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.